Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Ji, Wonjun ^a   Choi, Chang Min ^a   Rho, Jin K ^a   Jang, Se J ^a   Park, Young S ^a   Chun, Sung Min ^a   Kim, Woo S ^a   Lee, Jung Shin ^a   Kim, Sang We ^a   Lee, Dae H ^a   Lee, Jae C ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acquired resistance; EGFR tyrosine kinase inhibitor; Epidermal growth factor receptor mutation; Mass spectrometric genotyping; Non small cell lung carcinoma; Resistant mechanism

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SEQUENCE DELETION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84890965948     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-606     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967. 10.1056/NEJMoa0904554, 19692684.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957. 10.1056/NEJMoa0810699, 19692680.
4. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73. 10.1371/journal.pmed.0020073, 549606, 15737014.
5. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792. 10.1056/NEJMoa044238, 15728811.
6. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26. 3132801, 21430269.
7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043. 10.1126/science.1141478, 17463250.
8. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104(52):20932-20937. 10.1073/pnas.0710370104, 2409244, 18093943.
9. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012, 44(8):852-860. 10.1038/ng.2330, 3408577, 22751098.
10. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28(2):357-360. 10.1200/JCO.2009.24.7049, 19949011.
11. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4(11):e7887. 10.1371/journal.pone.0007887, 2774511, 19924296.
12. Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjos S, Hoivik EA, Wik E, Halle MK, Oyan AM, et al. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One 2012, 7(12):e52795. 10.1371/journal.pone.0052795, 3531332, 23300780.
13. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012, 7(6):e38892. 10.1371/journal.pone.0038892, 3377730, 22723903.
14. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17(5):1169-1180. 10.1158/1078-0432.CCR-10-2277, 3070951, 21248300.
15. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010, 2(5):146-158. 10.1002/emmm.201000070, 3377316, 20432502.
16. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17(5):1160-1168. 10.1158/1078-0432.CCR-10-2158, 21233402.
17. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29(16):2346-2356. 10.1038/onc.2009.526, 2859699, 20118985.
18. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17(6):1616-1622. 10.1158/1078-0432.CCR-10-2692, 3060283, 21135146.
19. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17(17):5530-5537. 10.1158/1078-0432.CCR-10-2571, 3166976, 21775534.
20. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19(6):754-764. 10.1016/j.ccr.2011.04.019, 21665149.
21. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116(10):2695-2706. 10.1172/JCI28656, 1570180, 16906227.
22. Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K, Abe H, Kage M, Yoshinaga A, et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One 2012, 7(7):e41017. 10.1371/journal.pone.0041017, 3398867, 22815900.
23. Honda Y, Takigawa N, Fushimi S, Ochi N, Kubo T, Ozaki S, Tanimoto M, Kiura K. Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors. Lung Cancer 2012, 78(1):121-124. 10.1016/j.lungcan.2012.07.003, 22835516.
24. Pantel K, Alix-Panabieres C. Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?. Cancer Res 2013, 73(21):6384-6388. 10.1158/0008-5472.CAN-13-2030, 24145355.
25. O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH, O'Byrne KJ. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012, 76(1):19-25. 10.1016/j.lungcan.2011.10.018, 22209049.